I-124 PET/CT for Thyroid Cancer Diagnosis

This study is looking at a new way to detect thyroid cancer using a special imaging scan called Iodine-124 (I-124) PET/CT. This scan uses a small amount of radioactive iodine (I-124) given by mouth, combined with PET (positron emission tomography) and CT (computerized tomography) scans. Researchers want to see how well this new scan compares to the standard imaging methods, I-123 and I-131 SPECT, for finding thyroid cancer, especially if it has spread. You may be able to join if you are at least 13 years old, have been diagnosed with differentiated or poorly differentiated thyroid cancer, and are planning I-131 treatment or meet other specific criteria. The study aims to see if the I-124 PET/CT scan agrees with the standard scans in detecting cancer.

Study design
This is a single-arm study, meaning all 62 participants will receive the same intervention. It is an interventional study, but the phase is not specified.
What's involved
You will have one PET/CT scan after taking I-124. You will be contacted by phone for 3-5 days to check for any side effects. Some participants may have up to two additional scans over five days.
Compensation
Not stated in the trial record.
Follow-up
You will be followed for adverse events for up to 3-5 days after the I-124 administration. The primary endpoints are measured at 1 day.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06961084

Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer

Recruiting
PHASE2Ages 13+InterventionalDiagnostic
Thomas Hope
~62 participants
Updated 2026-06-18 on ClinicalTrials.gov
What's tested:Iodine-124Positron Emission Tomography (PET)/Computerized tomography (CT)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Proportion of agreement between I-124 PET and I-123/I-131 SPECT (participant)
Measured over 1 day
+1 more outcome measured
Thyroid Cancer
1 sites across 1 states
California1
  • Thomas Hope, MD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco

Opens a ready-to-send draft in your own email app — review before sending.

  • Proportion of agreement between I-124 PET and I-123/I-131 SPECT (participant)1 day

    Participant-level agreement between I-124 PET and the combination of I-123/I-131 SPECT will be measured. A participant will be classified as showing agreement only if all six regions demonstrate agreement; disagreement in one or more regions will result in a classification of disagreement. Positive percent agreement (PPA) and negative percent agreement (NPA) will be reported with corresponding 95% confidence intervals.

  • Number of agreement between 1-124 PET and 1-123/1-131 SPECT (region)1 day

    Region-level agreement between 1-124 PET and the combination of 1-123/1-131 SPECT will be determined by Individual reader and through a consensus read. A region is in agreement if I-124 PET and I-123/I-131 SPECT results align, either as true positive (both positive) or true negative (both negative). Disagreement occurs when the results diverge, categorized as false positive (I-124 PET positive, but I-123/I-131 SPECT negative) or false negative (I-124 PET negative, but I-123/I-131 SPECT positive).